Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. reduced its position in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 32.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 156,871 shares of the company’s stock after selling 75,178 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Compass Therapeutics were worth $227,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rhumbline Advisers grew its holdings in Compass Therapeutics by 3.1% in the fourth quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock valued at $187,000 after purchasing an additional 3,822 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Compass Therapeutics by 2.6% in the 4th quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock valued at $345,000 after acquiring an additional 6,041 shares during the last quarter. Intech Investment Management LLC purchased a new position in Compass Therapeutics during the 3rd quarter valued at about $30,000. Independent Advisor Alliance acquired a new position in Compass Therapeutics during the fourth quarter worth about $26,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Compass Therapeutics by 0.8% in the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares in the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CMPX. Piper Sandler started coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. D. Boral Capital restated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, February 25th. Jefferies Financial Group increased their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, February 10th. Finally, Guggenheim started coverage on shares of Compass Therapeutics in a report on Monday, February 24th. They issued a “buy” rating and a $12.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Compass Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $11.38.

Compass Therapeutics Trading Up 2.6 %

Shares of NASDAQ:CMPX opened at $2.37 on Tuesday. The firm has a market cap of $327.73 million, a price-to-earnings ratio of -6.41 and a beta of 1.19. The stock’s 50-day moving average price is $2.88 and its two-hundred day moving average price is $2.09. Compass Therapeutics, Inc. has a 12-month low of $0.77 and a 12-month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, research analysts forecast that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.